查看完整行情页>>

|

货币单位:美元(USD)

居里

Curis, Inc. (cris)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
James E. Dentzer James E. Dentzer occupies the position of President, Chief Executive Officer & Director at Curis, Inc. In his past career he occupied the position of Chief Financial Officer of Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., Controller for Biogen, Inc., Chief Financial Officer for Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at E.I. du Pont de Nemours & Co. Mr. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
Kenneth I. Kaitin Kenneth I. Kaitin is on the board of Curis, Inc., Bio-Tree Systems, Inc. and Centerphase Solutions, Inc. and Director-Drug Development Study at Tufts Center for the Study of Drug Development. In his past career Dr. Kaitin occupied the position of President at Drug Information Association and Professor at Tufts University School of Medicine. He received a doctorate and a graduate degree from the University of Rochester and an undergraduate degree from Cornell University.
Martyn D. Greenacre Martyn D. Greenacre is a businessperson who has been at the helm of 8 different companies and presently occupies the position of Chairman for Life Mist Technologies, Inc. and Chairman for Curis, Inc. He is also on the board of Formula Pharmaceuticals, Inc. In the past he occupied the position of Chairman at Life Mist LLC, Chairman at Acusphere, Inc., Chief Executive Officer & Director at Delsys Pharmaceutical Corp., Chairman for Beijing Med-Pharm Corp., Chairman at BMP Sunstone Corp., President & Chief Executive Officer at Zynaxis, Inc., Senior Advisor at Arsenal Capital Management LP, Director & Chairman-European Operations at Smithkline Beecham Pharmaceuticals (India) Ltd. and Member-Executive Committee at Applera Corp. Martyn D. Greenacre received an MBA from Harvard Business School and an undergraduate degree from Harvard College.
James E. Dentzer James E. Dentzer occupies the position of President, Chief Executive Officer & Director at Curis, Inc. In his past career he occupied the position of Chief Financial Officer of Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., Controller for Biogen, Inc., Chief Financial Officer for Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at E.I. du Pont de Nemours & Co. Mr. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
Marc Rubin Marc Rubin is a businessperson who has been at the head of 5 different companies and presently occupies the position of Executive Chairman at Titan Pharmaceuticals, Inc. Dr. Rubin is also on the board of 5 other companies. In his past career Marc Rubin held the position of President & Chief Executive Officer at Titan Pharmaceuticals, Inc., Senior Vice President-Global Clinical Pharmacology at GlaxoSmithKline Plc, Chairman for Schering Berlin, Inc., President at Berlex Pharmaceuticals, Inc., Head-Global Research & Development at Bayer Pharma AG and Head-Global Research & Development at Bayer Schering Pharma AG. He received a doctorate from Weill Cornell Medical College.
Lori Anne Kunkel Lori Anne Kunkel is on the board of Curis, Inc., Tocagen, Inc., Nurix Therapeutics, Inc. and Maverick Therapeutics, Inc. and Owner at Lak505, LLC. In her past career Dr. Kunkel was Chief Medical Officer for Syndax Pharmaceuticals, Inc., Vice President-Clinical Development at Xencor, Inc., Chief Medical Officer of ACT Biotech, Inc., Principal at XOMA Corp., Vice President-Medical Affairs for Genitope Corp., Director at Loxo Oncology, Inc., Chief Medical Officer for Proteolix, Inc., Chief Medical Officer for Pharmacyclics LLC, Principal at Salmedix, Inc., Principal at Onyx Pharmaceuticals, Inc., Head-Clinical Scientist at Genentech, Inc., Principal at DNAX Research Institute of Molecular & Cellular Biology, Inc, Principal at ZymoGenetics, Inc., Associate Director-Clinical Development at Chiron Corp. and Member-Bone Marrow Transplant Unit at the University of California. She received an undergraduate degree from the University of California San Diego and a doctorate from the University of Southern California.
Robert E. Martell Robert E. Martell founded Epi-Cure Pharmaceuticals, Inc. Currently, he is Head-Research & Development at Curis, Inc. He is also Member of American Association for Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Professor at Tufts University School of Medicine and Member of American Society of Clinical Oncology. He previously was President & Director at Epi-Cure Pharmaceuticals, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Chief Medical Officer & Vice President at Mirati Therapeutics, Inc., Chief Medical Officer of TESARO, Inc., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center, Assistant Clinical Professor at Yale School of Medicine and Director-Neely Center at Clinical Cancer Research. He received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
Robert E. Martell Robert E. Martell founded Epi-Cure Pharmaceuticals, Inc. Currently, he is Head-Research & Development at Curis, Inc. He is also Member of American Association for Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Professor at Tufts University School of Medicine and Member of American Society of Clinical Oncology. He previously was President & Director at Epi-Cure Pharmaceuticals, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Chief Medical Officer & Vice President at Mirati Therapeutics, Inc., Chief Medical Officer of TESARO, Inc., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center, Assistant Clinical Professor at Yale School of Medicine and Director-Neely Center at Clinical Cancer Research. He received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
Robert E. Martell Robert E. Martell founded Epi-Cure Pharmaceuticals, Inc. Currently, he is Head-Research & Development at Curis, Inc. He is also Member of American Association for Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Professor at Tufts University School of Medicine and Member of American Society of Clinical Oncology. He previously was President & Director at Epi-Cure Pharmaceuticals, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Chief Medical Officer & Vice President at Mirati Therapeutics, Inc., Chief Medical Officer of TESARO, Inc., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center, Assistant Clinical Professor at Yale School of Medicine and Director-Neely Center at Clinical Cancer Research. He received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
Robert E. Martell Robert E. Martell founded Epi-Cure Pharmaceuticals, Inc. Currently, he is Head-Research & Development at Curis, Inc. He is also Member of American Association for Cancer Research, Associate Chief-Division of Hematology/Oncology at Tufts Medical Center, Inc., Professor at Tufts University School of Medicine and Member of American Society of Clinical Oncology. He previously was President & Director at Epi-Cure Pharmaceuticals, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Chief Medical Officer & Vice President at Mirati Therapeutics, Inc., Chief Medical Officer of TESARO, Inc., Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Associate Professor at Tufts Medical Center, Inc., Assistant Professor at Duke University Medical Center, Assistant Clinical Professor at Yale School of Medicine and Director-Neely Center at Clinical Cancer Research. He received an undergraduate degree from Kalamazoo College, a doctorate from the University of Michigan and a doctorate from Wayne State University (Michigan).
James E. Dentzer James E. Dentzer occupies the position of President, Chief Executive Officer & Director at Curis, Inc. In his past career he occupied the position of Chief Financial Officer of Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., Controller for Biogen, Inc., Chief Financial Officer for Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at E.I. du Pont de Nemours & Co. Mr. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
James E. Dentzer James E. Dentzer occupies the position of President, Chief Executive Officer & Director at Curis, Inc. In his past career he occupied the position of Chief Financial Officer of Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., Controller for Biogen, Inc., Chief Financial Officer for Valeritas, Inc. and Chief Financial Officer-DuPont Flooring Systems at E.I. du Pont de Nemours & Co. Mr. Dentzer received an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
William E. Steinkrauss William E. Steinkrauss occupies the position of Chief Financial Officer & Treasurer of Curis, Inc. In his past career he was Director-Technical Accounting & Reporting at OvaScience, Inc. and Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC. He received a graduate degree and an undergraduate degree from Boston College.
Reinhard von Roemeling Reinhard von Roemeling holds the position of Senior Vice President-Clinical Development at Curis, Inc. He received a doctorate from Goethe University Frankfurt.
Christine Guertin Christine Guertin is VP-Regulatory Affairs & Quality Assurance at Curis, Inc. Ms. Guertin received an undergraduate degree from Saint Joseph's College (Indiana) and a graduate degree from Regis College.